Alexion Pharmaceuticals, Inc. ALXN announced new data from the extension phase of an ongoing phase II study on Strensiq. The data was presented at the annual meeting of the American Society for Bone and Mineral Research (ASBMR).
In the open-label, phase II study evaluating the use of Strensiq in children with hypophosphatasia (HPP) for at least five years, it was found that children treated with Strensiq experienced significant healing of HPP-related skeletal manifestations and improvements in physical function within three to six months from treatment onset, which were sustained through five years of treatment. Apart from that clinically significant improvements in functional mobility compared to historical controls were observed in patients with juvenile-onset HPP in the Strensiq arm.
We note that Strensiq is already approved in Japan for the treatment of patients with HPP and in the EU and Canada for the treatment of patients with pediatric-onset HPP. Alexion has submitted a biologics license application for Strensiq to the FDA and has been granted priority status for the same.
We are pleased with the pipeline progress at Alexion. Approval of new products is expected to substantially reduce the company’s dependence on Soliris for growth.
Alexion carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Anika Therapeutics Inc. ANIK, Amgen Inc. AMGN and Eli Lilly and Company LLY. Anika and Amgen hold a Zacks Rank #1 (Strong Buy), while Eli Lilly is a Zacks Rank #2 (Buy) stock.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment